Stockreport
Sale Of Sandoz: Will They Or Won't They? [Seeking Alpha]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
Sale Of Sandoz: Will They Or Won't They? Rumors and announcements have left Novartis (NYSE: NVS Richard Francis, CEO of Sandoz, will be resigning. Now, having Sandoz operate as an automated entity certainly could be interpreted as a move towards the ultimate divestiture of it, but then again, when the Chairman states the exact opposite, it makes investors wonder why the company has made this move in the first place. Overview of Sandoz Sandoz is the generic and biosimilar medicines division within Novartis. They are currently number 1 globally in biosimilars and generic antibiotics, dermatology, and transplantation medicines. They are also known for having received approval for the first-ever generic biotech drug way back in 2006. Sandoz's Historical Advantage Pharmaceutical companies have always struggled with patent cliff issues. Patent cliff issues arise when billions of dollars in revenue are linked to a small number of drugs that are reaching the end of their respective patents. A
[Read more]
IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
LAST PRICE | ||
VWAP | ||
High:
|
MAX UP |
High:
|
Low:
|
MAX DOWN |
Low:
|
%
|
POST NEWS RANGE |
%
|
|
PRICE CHANGE |
|
|
PRICE CHANGE PERCENTAGE |
|
|
S&P 500 (SPX) |
|
%
|
VOLUME RATIO |
%
|
VOLUME (SHARES) | ||
TICKS | ||
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- Biologic Therapeutics Drugs Market Size Projections Exhibit a CAGR of 12.2%%, Likely to Attain a Value of USD 1485.0 Billion by 2033 [Yahoo! Finance][Yahoo! Finance]
- Microbial Products Market to Gain $286.53 Billion, by 2033 with 6% CAGR: States The Brainy Insights [Yahoo! Finance][Yahoo! Finance]
- Why Amgen (AMGN) Outpaced the Stock Market Today [Yahoo! Finance][Yahoo! Finance]
- 3 Generic Drug Stocks to Watch Amid Challenging Market Prospects [Yahoo! Finance][Yahoo! Finance]
- Amgen Inc. (NASDAQ: AMGN) had its price target lowered by analysts at UBS Group AG from $314.00 to $284.00. They now have a "neutral" rating on the stock.[MarketBeat]
- More
AMGN
SEC Filings
SEC Filings
- 4/17/24 - Form DEFA14A
- 4/17/24 - Form DEF
- 4/10/24 - Form ARS
- AMGN's page on the SEC website
- More